ENTITY
Biogen Inc

Biogen Inc (BIIB US)

130
Analysis
Health CareUnited States
Biogen Inc. develops, manufactures, and commercializes therapies, focusing on neurology, oncology, and immunology. The Company's products address diseases such as multiple sclerosis, non-Hodgkin's lymphoma, rheumatoid arthritis, Crohn's disease, and psoriasis.
more
bullishBiogen Inc
22 Feb 2025 10:00

Biogen Inc.: Expansion into Immunology & Rare Diseases Is Key Diversification Strategy But Will It Work?

Biogen Inc.'s fourth-quarter and full-year 2024 financial results highlight a company in transition, balancing the challenges of competition in...

Logo
335 Views
Share
bullishBiogen Inc
08 Nov 2024 19:00

Biogen Inc.: Market Expansion & Commercial Execution Of New Launches Driving Our 'Buy' Rating! - Major Drivers

Biogen's third-quarter 2024 earnings highlighted both strides and challenges the company is navigating in its ongoing operations and strategic...

Logo
361 Views
Share
bullishBiogen Inc
12 Aug 2024 06:00

Biogen Inc.: How Is Their Expansion and Execution of New Product Launches Going? - Major Drivers

Biogen recently reported its earnings for the second quarter of 2024. The company, a leading biotechnology entity known for its pioneering work in...

Logo
212 Views
Share
17 Dec 2024 10:32

Nasdaq100 December 2024 Forecast (Final): Palantir's Last-Minute Entry; Arm's Subtle Retention

F1: 100%. All of the forecasts matched the index changes announced at the close of Friday 13 December. SMCI fell more than 11% in premarket trading...

Logo
844 Views
Share
03 Mar 2025 01:55

Strategic Reviews, Mergers, and Asset Sales: Analyzing Upside Potential in Active Portfolio Ideas

Sage Therapeutics rejected Biogen's $7.22/share offer, initiating a strategic review for potential sale, indicating a possible higher premium.

Share
x